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Abstract Certain exogenously-supplied sterols, like ergost-8-
enol, are efficiently converted into ergosterol in yeast. We have
taken advantage of this property to study the regulation of the
v8-v7-sterol isomerase-encoding ERG2 gene in an ergosterol
auxotrophic mutant devoid of squalene-synthase activity. Ergo-
sterol starvation leads to an 8^16-fold increase in ERG2 gene
expression. Such an increase was also observed in wild-type cells
either grown anaerobically or treated with SR31747A a sterol
isomerase inhibitor. Exogenously-supplied zymosterol is entirely
transformed into ergosterol, which represses ERG2 transcription.
By contrast, exogenously-supplied ergosterol has little or no
effect on ERG2 transcription.
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1. Introduction
The yeast ERG2 gene encodes v8-v7-sterol isomerase, an
enzyme of the sterol biosynthetic pathway. This enzyme is the
target for several active agents exhibiting antifungal [1], im-
munosuppressive [2], and/or neuroprotective properties [3].
Sterol isomerase together with 14-sterol reductase constitute
the two main targets for the morpholine and piperidine deriv-
ative family of sterol biosynthesis inhibitors. This group in-
cludes several structurally-related molecules, such as fenpro-
pimorph and fenpropidine, that are widely used in agriculture
against cereal powdery mildew [4].
SR31747A is a highly selective v8-v7-sterol isomerase in-
hibitor that is e¡ective against the yeast enzyme [5] as well as
against the structurally and phylogenetically unrelated mam-
malian v8-v7-sterol isomerase [2,6,7]. SR31747A displays im-
munosuppressive properties [8] that appear to be mediated by
the ERG2 ortholog in mammals, namely the subtype 1 of the
so-called ‘sigma receptors’ (sigma1) also known as SR31747A-
binding protein [3,9]. This drug also exhibits anti-proliferative
properties in mammalian cells, that are obtained through the
inhibition of the high-eukaryote-speci¢c type of v8-v7-sterol
isomerase [7]. Finally, inhibition of neuronal cholesterol bio-
synthesis is thought to induce the long-term neuroprotective
properties exhibited by sterol isomerase ligands [2]. Thus, ster-
ol isomerase appears to be a target of paramount importance
for both agricultural and pharmaceutical issues.
In this work, we have checked whether ERG2 gene expres-
sion is regulated at the transcriptional level in yeast. Unlike in
previous studies [10^12], we have used a sterol auxotrophic
strain to examine if gene expression could be up-regulated by
ergosterol deprivation, or down-regulated by sterol intermedi-
ates accumulating at high concentrations. In addition, as the
sterol uptake and intracellular tra⁄cking mechanisms are not
well understood, we have examined the uptake and the bio-
transformation of various ergosterol precursors.
With the exception of lanosterol, all the sterol species tested
were e⁄ciently converted into ergosterol. We could demon-
strate that ergosterol, when taken up directly from the growth
medium, had little or no e¡ect on ERG2 transcription, where-
as ergosterol synthesised from an exogenously-supplied pre-
cursor, like zymosterol, dramatically repressed ERG2 tran-
scription.
2. Materials and methods
2.1. Construction of the LacZ-expressing cassette placed under the
control of the ERG2 promoter
Strain EMA4 (MATa, ura3-251, ura3-373, ura3-328, trp1-4) is a
congenic derivative of FL100 (ATCC 28383). Plasmid pEMR1465 is
an integrative plasmid that contains a wild-type (wt) version of the
URA3 gene and the lacZ gene placed under the control of the ERG2
promoter. The ERG2 promoter-encompassing region that £anks lacZ
starts at coordinate 1930 of chromosome XIII (Accession number
Z48755). The 3P-end of this chromosome XIII-derived fragment in-
cludes the sixth codon of the ERG2 coding sequence fused in frame
with the LacZ sequence derived from Yep 358 [13]. StuI-linearised
pEMR1465 DNA was used to transform EMA4 to Ura. One trans-
formant, namely EMA90-3, was chosen, that harboured four copies
of pEMR1465 integrated as direct repeats inside the URA3 locus.
2.2. Construction of EK9-2 sterol auxotroph
Strain EMA90-3 was crossed with the ERG9 gene disruptant MK
5306 (MATK, erg9: :HIS3, aux32, ura3-1, leu2-1, ade2-1, his3-1). The
latter strain is devoid of squalene synthase and therefore requires
sterol for growth. The diploid was induced to sporulate, asci were
dissected, and single-spore colonies were obtained under anaerobic
conditions on complete medium supplemented with 10 ml/l of a solu-
tion of Tween 80/ethanol (v/v), containing 4 mg/ml ergosterol and
10 mg/ml oleate. Sterol auxotrophy was tested under aerobic condi-
tions and L-galactosidase production was ascertained by the X-Gal
assay. Clone EK9-2 (erg9: :HIS3, aux32, URA3: :pERG2-LacZ, leu2-
1) was retained for further studies.
2.3. Sterol uptake and metabolism
Strain EK9-2 was grown in YPD medium supplemented with either
ergosterol, lanosterol, 24-demethyl sterols or v8-sterols. Demethyl-24
sterols were prepared from an ERG6 gene disruptant devoid of
24-methyl transferase. A mixture of v8-sterols was prepared from a
double ERG2, FEN1 disruptant. FEN1 gene disruption allows ERG2
gene disrupted cells to proliferate in the absence of ergosterol [2].
Zymosterol was prepared from a double ERG2, ERG6 disruptant.
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For uptake studies, sterols (10 Wg/ml, ¢nal concentration) were sup-
plied by dilution of a stock solution (4 mg/ml) in a mixture of Tergitol
NP40 (Sigma)-ethanol (v/v). Cells were cultured at 30‡C for 30 h, then
harvested and freeze dried. After saponi¢cation, the ergosterol/ergo-
sta-5,7-dienol and the overall sterol amounts were determined by UV
spectrophotometry and gas chromatography (GC), respectively [14].
2.4. L-Galactosidase assay
L-Galactosidase activity was assayed directly on entire cells permea-
bilised by N-lauroylsarcosine treatment, as already described [15].
Activity was expressed in arbitrary units (OD/min/cell density unit).
2.5. Northern blot
Analyses were performed as described [16]. The ERG2 and ACT1
probes were obtained by PCR ampli¢cation of an ERG2 gene segment
(nt positions 266^977 of sequence M74037 in GenBank/EMBL data-
base) and of an ACT1 gene segment (nt positions 426^1150 of se-
quence V011288 in GenBank/EMBL database), respectively. PCR
products were labelled with 32P-Q-ATP by a conventional nick-trans-
lation procedure [16].
3. Results
3.1. Sterol transport and metabolism in yeast
To facilitate the study of the e¡ects of various sterol species
on yeast ERG2 gene transcription, we used an ERG9 gene
disrupted strain, MK 5306. The ERG9 gene encodes squalene
synthase, the enzyme catalysing the ¢rst speci¢c step of the
sterol branch of the isoprenoid pathway. Thus, cells deleted
for ERG9 do not synthesise sterols de novo and are strictly
dependent on uptake to proliferate. Yeast cells are generally
unable to take up exogenous sterols in the presence of oxygen.
A way to restore aerobic viability in an Erg3 mutant is to
block heme biosynthesis [17] or to over-express certain genes,
like SUT1 [18], both strategies resulting in sterol uptake com-
petency. In our strain MK 5306, sterol uptake capability was
conferred by the presence of the leaky aux32-1 mutation that
a¡ected the pyridoxal phosphate oxidase gene and conse-
quently decreased heme biosynthesis [19].
We checked the e⁄cacy of sterol uptake and metabolisation
in strain MK5306. The ¢rst observation is that the ergosterol
level remains three-fold lower than in the congenic wt strain
FL100, even when the cells are supplied with ergosterol at
saturating concentrations (Table 1). The conversion of choles-
ta-5,7,24-trienol into ergosterol is a three-step process that
involves a 24-transmethylase localised in lipid droplets [20]
and a v24-sterol reductase and a v22 desaturase localised in
the endoplasmic reticulum (ER). Therefore, sterol tra⁄cking
between plasma membrane, ER and lipid droplets is required
for metabolisation into ergosterol. The conversion of ergost-8-
enol into ergosterol requires three enzymatic steps: v8-v7-
sterol isomerase, v5-sterol desaturase and v22-sterol desatur-
ase, these three enzymes being localised in the ER membranes.
Cholesta-5,7,24-trienol on the one hand and ergost-8-enol on
the other hand, are converted into ergosterol with an e⁄-
ciency of about 90% (Table 1). This result indicates that these
sterol species are transported from the plasma membrane to
the various subcellular compartments containing sterol bio-
synthetic enzymes. However, the total sterol level is about
three-fold lower than that in wt, whatever the type of sterol
supplied, which reveals that uptake is the rate-limiting step in
the in vivo conversion of precursors into ergosterol. Lanoster-
ol was found not to be metabolised at all and did not support
growth in MK5306. As an attempt to estimate the speed of
sterol conversion, the wt strain FL100 was cultured overnight
in the presence of fenpropimorph at a concentration su⁄cient
to signi¢cantly inhibit ergosterol biosynthesis without arrest-
ing cell proliferation (0.7 WM), then the cells were washed and
suspended in fresh medium without inhibitor. The fate of the
two major sterol species that had been accumulated during
treatment with the inhibitor, ergost-8-enol and ergosta-8,14-
dienol (ignosterol) was then followed by GC analysis. Surpris-
ingly, ergost-8-enol and ignosterol amounts remained constant
even in cells grown in drug-free medium for 23 h (Table 2,
Table 1
Sterol uptake and metabolism during growth in MK 5306 (erg9: :HIS3) strain
Sterol supplied Growth Yield 5,7-Sterol level Sterol Uptake GC Analysis
Ergosterol 208 0.30 62% Ergosterol 100%
Cholesta-5,7,24-trienola 216 0.32 69% Ergosterol 100%
Ergost-8-enola 204 0.23 65% Ergosterol 72%
Zymosterol 25%
Ergost-8-enol 3%
Lanosterol 8 NT NT NT
^ 1 NT NT NT
Growth yield is expressed in mg dry weight, after a 30 h growth period at 28‡C. 5,7-Sterol level (sum of ergosterol and ergosta-5,7-dienol) was
determined from the UV spectrum of non-saponi¢able lipid fraction and expressed in percent of cell dry weight (in wt strain the 5,7-sterol level
is 0.76%). Sterol uptake is expressed in percent relative to total sterol amount provided in growth medium. The GC analysis gives the percent
of each individual sterol. NT = not tested
aMain sterols in mixtures of 24-demethyl-sterols (cholesta-5,7,24-trienol 79% and cholesta-5,7,22,24-tetraenol 21%) and v8-sterols (ergost-8-enol
75%, ignosterol 10% and zymosterol 15%). Sterols were supplied at 10 Wg/ml ¢nal concentration in 100 ml YPD medium.
Fig. 1. Northern blot analysis of ERG2 and ACTIN mRNAs in wt
and in a ERG24 gene disruptant. Steady state levels of actin mRNA
were supposed to be constant in both strains, so variations in actin
mRNA were supposed to represent di¡erences in loaded material
amounts. Signal intensity of each band was quanti¢ed by a phos-
phoimager apparatus, and variations in ERG2 signal intensity from
one strain to another were corrected by the corresponding actin sig-
nal variations.
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part A). The experiment was repeated with a FEN1 gene dis-
ruptant, namely ISA1 [21]. Loss of Fen1p relieves cells from
the fenpropimorph-induced antiproliferation arrest, although
fenpropimorph induces the accumulation of the same sterol
species whether Fen1p is present or not [2,21]. In fen1 as in
wt, ergost-8-enol and ignosterol that were accumulated upon
fenpropimorph treatment were not converted into ergosterol,
after removal of the anti-fungal agent, although v8-v7-sterol
isomerase and v14-sterol reductase were functional as indi-
cated by the restoration of ergosterol biosynthesis (Table 2,
part B). Therefore, the conversion speed could not be assessed
by this approach.
3.2. ERG2 mRNA steady state levels increase in a mutant
impaired in ergosterol biosynthesis
To test whether ERG2 gene expression could be modulated
transcriptionally, ERG2 mRNA levels were compared in a
Erg strain and in a congenic ERG24 gene disruptant. In
the latter strain, which lacks 14-sterol reductase, the sterol
pathway ends with ignosterol, and no ergosterol is produced.
Loss of Erg24p correlated with a 8^9-fold increase in ERG2
mRNA level (Fig. 1). As a control, loss of Fen1p or Sur4p,
two similar ER membrane proteins that are required for sen-
sitivity to the antiproliferative e¡ects of various sterol biosyn-
thesis inhibitors, had no consequence on ERG2 mRNA steady
state levels (not shown).
3.3. L-Galactosidase assays con¢rm that ERG2 transcription is
regulated
Northern blot results indicated that the steady state level of
sterol isomerase-encoding mRNA was enhanced in cells in
which ergosterol biosynthesis was impaired. This result sug-
gested that ERG2 expression could be controlled at the tran-
scriptional level. To verify this point, we tested the e¡ect of
SR31747A, at various concentrations, on L-galactosidase pro-
duction in EMA90, an Erg strain that harbours four direct
repeats of the bacterial LacZ gene placed under the control of
the ERG2 gene promoter at the URA3 locus. The addition of
10 nM SR31747A into the culture medium was su⁄cient to
enhance L-galactosidase production by three-fold. This factor
still increased in a SR31747A-dependent manner, to reach a
plateau at drug concentrations exceeding 0.5 WM (Fig. 2). At
these concentrations, L-galactosidase production was 15 to 16-
Table 2
Metabolism of ergost-8-enol and ignosterol after fenpropimorph treatment
Time (h) Cell yield 5,7-Dienols GC analysis; total sterols (%)
Lanosterol Zymosterol Ergost-8-enol Ignosterol Ergosterol
Part A: wt strain
0 32 0.08 17 ND 41 41 6 1
1.5 32 0.09 17 ND 43 40 6 1
3 32 0.10 18 ND 44 37 6 1
6 32 0.29 16 ND 45 39 6 1
23 162 0.49 1 12 46 24 12
Part B: Strain ISA1 (fen1: :URA3)
0 186 0.09 2 9 73 16 6 1
1 199 0.15 4 10 65 21 6 1
2 234 0.29 3 12 51 17 16
3 371 0.49 1 14 44 7 34
Cells were inoculated at OD (700 nm) 0.1 unit/ml in 500 ml YPD containing 0.7 WM fenpropimorph and cultured under shaking at 28‡C dur-
ing 15 h. Cells were collected by centrifugation and washed two-fold with YPD medium, then inoculated in 500 ml YPD medium and cultured
at 28‡C. At the time indicated, aliquots of 100 ml were collected. Freeze dried cells were saponi¢ed and the sterol content analysed. Cell yield
was expressed in mg dry weight. 5,7-Dienol level was determined from the UV spectrum and expressed in percent of cell dry weight.
Table 3
L-Galactosidase activity in EK9-1 cells fed with various sterols
Sterol supplied L-Galactosidase speci¢c activity
Exp. 1 Exp. 2
Cholesterol 19.5 17.8
Ergosterol 17.2 20.3
Zymosterol 7.7 8.7
Cells were grown in YPD supplemented with Tergitol NP40 (Sigma)
and 25 mg/l cholesterol for 30 h, then an aliquot was used to inocu-
late growth medium di¡ering only by the sterol source as indicated.
Starting OD value was 0.05 units/ml. Cells were grown for 24 h and
then tested for L-galactosidase activity. Exp.1 and Exp.2 are two in-
dependent experiments. In each case, cell ergosterol amounts were
quanti¢ed. Ergosterol was below level of detection in cholesterol-fed
cells, whereas it represented about 0.4% of cell dry weight in ergo-
sterol or zymosterol-fed cells.
Fig. 2. SR31747 e¡ect on ERG2 promoter-controlled lacZ gene ex-
pression in yeast.
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fold higher than in the absence of the drug. Taken together,
these results indicated that a block in the sterol biosynthetic
pathway, achieved either by deleting ERG24 gene or by in-
hibiting v8-v7-sterol isomerase, provoked an 8^16-fold in-
crease in ERG2 gene transcription. As this block leads to
the accumulation of distinct sterol species, v8-14 and v8-ster-
ols, respectively, it seemed likely that it was ergosterol, and
not the intermediate compounds accumulated, that modulated
ERG2 gene transcription. To address this issue, we con-
structed a squalene synthase-defective strain that contained
four copies of the ERG2-controlled lacZ construct. This
strain, namely EK9-2, was unable to synthesise sterols and
proliferated only in the presence of exogenously-supplied ster-
ols. This strain was starved for ergosterol by subsequent cul-
tures in medium containing cholesterol as the sole source of
sterol. No sterol species other than cholesterol was detected in
these cells (not shown), which was expected as cholesterol is
not metabolised by Saccharomyces cerevisiae [18]. The L-ga-
lactosidase level in these ergosterol-starved cells was found to
be maximal, and similar to that observed in wt cells treated
with high concentrations of SR31747A (Table 3). This result
indicated that intermediates of the ergosterol biosynthesis
pathway were not required for maximal induction of sterol
biosynthesis gene expression. However, when cholesterol was
replaced by ergosterol, L-galactosidase production did not de-
crease at all, although exogenously-supplied ergosterol was
incorporated at a level reaching approximately 40% that nor-
mally found in wt cells. This result suggested that exoge-
nously-supplied ergosterol was not competent for sterol bio-
synthesis gene regulation. When fed with zymosterol, these
cells biosynthesised ergosterol which reached a level similar
to that found in ergosterol-fed cells. However, L-galactosidase
production was reduced by two to three-fold in zymosterol-
fed cells, suggesting that ergosterol had to be biosynthesised,
rather than provided exogenously, to exert a regulatory role
on sterol biosynthesis. Similar results were obtained by com-
paring the L-galactosidase levels in an Erg strain grown
under aerobic and anaerobic conditions. Under the latter con-
dition ergosterol biosynthesis is blocked at the squalene epoxi-
dase step, no sterol is produced and ergosterol has to be
provided as an exogenous source. L-Galactosidase production
was enhanced 5^11-fold in cells grown in the absence of oxy-
gen (Table 4), suggesting here again, that exogenous ergoster-
ol exerts no inhibitory e¡ect on ERG2 gene transcription.
4. Discussion
Using a squalene synthase-defective strain, we could show
that exogenously-supplied sterol molecules, except lanosterol,
were e⁄ciently converted into ergosterol. These results unam-
biguously demonstrate that sterols taken up from the medium
by yeast cells can reach the subcellular compartments where
sterol biosynthesis enzymes are localised. The lack of lanoster-
ol bioconversion, as already described by Bard et al. [22],
might point to a speci¢c defect in lanosterol uptake or intra-
cellular tra⁄cking rather than to a defect in metabolism, since
aux32 cells are indeed able to synthesise ergosterol [23]. We
have shown that the intermediate sterols accumulated upon
fenpropimorph treatment, are not metabolised after drug re-
moval, even when ergosterol biosynthesis is restored. It has
already been shown that these sterol intermediates are accu-
mulated chie£y under an esteri¢ed form [24]. As steryl esters
are stored in lipid droplets [20,25], it can be deduced that
these sterol intermediates are accumulated chie£y in lipid
droplets, instead of being used as constituents of the plasma
membrane. Our experiments suggest the absence of steryl ester
transfer from lipid droplet to ER membrane. This observation
contrasts with the postulated tra⁄cking of free sterol from
lipid particles to ER membrane during sterol biosynthesis.
This apparent contradiction could point to the existence of
(a) transporter(s) that speci¢cally transfer free sterol, and
not steryl esters, from lipid droplets to ER membrane. It is
worth noting that the normal routing for steryl esters is from
lipid particles to plasma membrane, which enables their uti-
lisation as shown by Taylor and Parks [26].
ERG2 transcription is induced in the absence of ergosterol,
or repressed in its presence, to an extent similar to that re-
ported for ERG3. Our data are in good agreement with a
recent work showing that ERG2 gene is the most strongly
induced gene amongst those in isoprenoid pathway, in yeast
cells treated with sterol biosynthesis inhibitors [12]. We show
however that ergosterol supplied exogenously has little or no
e¡ect on this regulation. This observation is consistent with
previous results from Servouse and Karst [27] who demon-
strated that exogenously-supplied ergosterol did not a¡ect
the speci¢c activity of various sterol biosynthetic enzymes,
including acetoacetyl-CoA thiolase, HMG-CoA synthase
and HMG-CoA reductase. A possible explanation is that er-
gosterol, or an immediate metabolite, has to be present in a
particular cell compartment, possibly the ER membrane or
the nuclear envelope, to correctly regulate expression of its
own biosynthetic genes. Exogenously-supplied ergosterol
would be partly incorporated in plasma membrane, and the
excess stored as steryl ester in lipid droplets, which would
impede tra⁄c back to the ER membrane and its perinuclear
prolongation.
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